When was Celgene founded?

Celgene was founded in 1986 and raised its 1st funding round 22 years after it was founded.

Where is Celgene located?

Celgene is headquartered in Summit, United States.

How many employees does Celgene have?

As of Dec 31, 2020, Celgene has 4891 employees, reflecting a 13% year-over-year decline in headcount.

Is Celgene a funded company?

Celgene is a funded company, having raised a total of $45M across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Oct 26, 2008.

When was the latest funding round of Celgene?

Celgene's latest funding was a $***** Post IPO round on Feb 10, 2018, with participation from 1 investor. Its primary sector is Biopharma Outsourcing. In United States, the Biopharma Outsourcing sector has seen $256M in funding in 2026 to date.

Where does Celgene rank among its competitors?

Celgene ranks 61st amongst 622 active competitors, of which 133 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Lyell Immunopharma, which secured $100M in Jul, 2025.

Who are the top competitors of Celgene?

Celgene's top competitors include Kite Pharma, Juno Therapeutics and ImmunoACT. Among them, Lyell Immunopharma secured the most recent funding round in July, 2025.

Celgene - 2026 Company Profile, Funding & Competitors

Celgene is an acquired company based in Summit (United States), founded in 1986. It operates as a Developer of therapies for treating cancer and inflammatory diseases. Celgene has raised $45M in funding. The company has 622 active competitors, including 133 funded and 185 that have exited. Its top competitors include companies like Kite Pharma, Juno Therapeutics and ImmunoACT.

Company Details

Celgene is developing therapies for multiple myeloma, inflammatory diseases, and various forms of cancer. The company's lead molecule BCMA CAR T is used for treating multiple myeloma. The candidate is in phase II clinical study. Other candidates are in phase I and II, used for treating various cancers. In 2018, the company recorded annual revenues of $15.28B, and a net profit of $4.04B.

Website: celgene.com
Social
Part Of

Key Metrics

Founded Year

1986

Location

Summit, United States

Stage

Acquired

Total Funding

$45M in 8 rounds

Latest Funding Round

Post IPO, Feb 10, 2018, $*****

Investors

Piper Jaffray & 13 more

Ranked

61^st among 622 active competitors

Employee Count

4,891 as on Dec 31, 2020

Investment & Acquisitions

Cyteir & 78 more

Similar Companies

Kite Pharma & 318 more

Exit Details

Acquired by Bristol-Myers Squibb (Jan 03, 2019)

View Celgene's full profile

Celgene is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Celgene CIN: - , Belgium, Active		-	4891 (As on Dec 31, 2020)	-

Celgene got acquired by Bristol-Myers Squibb on Jan 03, 2019 at an acquisition amount of $74B. It was facilitated by Morgan Stanley, Citi, Evercore and 4 more.

Click here to take a look at Celgene's acquisition in detail

Celgene has raised a total funding of $45M over 8 rounds. Its first funding round was on Oct 26, 2008. Its latest funding round was a Post IPO round on Feb 10, 2018 for $*****. 1 investor participated in its latest round. Celgene has 14 institutional investors.

Here is the list of recent funding rounds of Celgene:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 10, 2018	5068744	Post IPO	1929719	8805730	3352941	4124100
Nov 01, 2017	1223464	Conventional Debt	9956388	9115350	1558262	6697411
Apr 13, 2015	3591480	PE	2469744	9518312	5662683	Mesoblast

Access funding benchmarks and valuations. Sign up today!

View details of Celgene's funding rounds and investors

Celgene's employee count trend

Celgene has 4,891 employees as of Dec 20. The total employee count is 14.0% lower than what it was in Dec 19. Here is Celgene's employee count trend over the years:

Uncover Celgene's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Celgene include Kite Pharma, Juno Therapeutics and ImmunoACT. Here is the list of Top 10 competitors of Celgene, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, BB Biotech & 10 others	75/100
2nd	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	Omega Funds, BB Biotech & 14 others	74/100
3rd	ImmunoACT 2018, Mumbai (India), Series B	Developer of cell and gene therapies for cancer treatment	$15.9M	SINE, Laurus Labs & 3 others	69/100
4th	Achilles Therapeutics 2016, London (United Kingdom), Public	Developer of T-cell therapies for cancer	$242M	Boxer Capital, Orbimed & 41 others	69/100
5th	Cabaletta Bio 2017, Radnor (United States), Public	Developer of CAAR T cells for B cell-mediated autoimmune diseases	$88.3M	Boxer Capital, Deerfield & 5 others	67/100
6th	Lyell Immunopharma 2018, San Francisco (United States), Public	Developer of CAR- T therapy for cancer treatment	$493M	Sahsen Ventures, GSK & 5 others	66/100
7th	Cargo Therapeutics 2021, San Mateo (United States), Acquired	Developer of cell-based therapeutics for cancer treatment	$200M	RTW Investments, Xontogeny & 13 others	66/100
8th	Autolus 2015, London (United Kingdom), Public	Developer of engineered T-cell immunotherapy for cancer and auto-immune diseases	$181M	Syncona, 4Bio Capital & 7 others	65/100
9th	Iovance 2007, San Carlos (United States), Public	Developer of T-cell therapies for the treatment of cancer	-	Colt Ventures, Orbimed & 4 others	65/100
10th	CG Oncology 2010, Irvine (United States), Public	Developer of immunotherapeutic agents for treating cancer	$318M	ORI Capital, Foresite Capital & 16 others	64/100
61st	Celgene 1986, Summit (United States), Acquired	Developer of therapies for treating cancer and inflammatory diseases	$45M	Piper Jaffray, BB Biotech & 12 others	56/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Celgene's competitors? Click here to see the top ones

Celgene has made 68 investments in companies including Cyteir and Anokion. Celgene has also acquired 11 companies including Delinia and Acetylon.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Oct 14, 2019	Investments	Cyteir	2012	Cambridge (United States)
Sep 11, 2019	Investments	Anokion	2010	Ecublens (Switzerland)
Aug 21, 2019	Investments	Oncorus	2016	Cambridge (United States)